血管生成素作为急性肾损伤后未来肾脏疾病与心力衰竭事件的预后标志物
这项前瞻性队列研究纳入1503例住院患者(746例有AKI),出院3个月后检测血浆血管生成素-1与血管生成素-2比值。在AKI患者中,该比值最高四分位与CKD进展、心力衰竭和死亡风险显著降低相关;无AKI者仅心力衰竭和死亡风险降低,与CKD进展无关。
要点
- AKI患者中Angpt-1:Angpt-2比值最高四分位与CKD进展风险降低72%相关。
- AKI患者中该比值最高四分位与心力衰竭风险降低94%、死亡风险降低82%相关。
- 无AKI者中该比值最高四分位与心力衰竭和死亡风险降低相关,与CKD进展无关。
核心结论
- 较高的Angpt-1:Angpt-2比值在AKI背景下与较少的CKD进展、心力衰竭和死亡强烈相关。
研究设计与样本
- 前瞻性队列研究,纳入1503例住院患者,中位年龄65.8岁,746例(50%)有AKI,出院3个月后评估血浆血管生成素与结局的关联。
主要发现
- AKI患者中,Angpt-1:Angpt-2比值最高四分位与CKD进展风险降低72%相关(aHR 0.28;95%CI 0.15至0.51)。
- AKI患者中,该比值最高四分位与心力衰竭风险降低94%相关(aHR 0.06;95%CI 0.02至0.15)。
- AKI患者中,该比值最高四分位与死亡风险降低82%相关(aHR 0.18;95%CI 0.09至0.35)。
- 无AKI者中,该比值最高四分位与心力衰竭风险降低71%相关(aHR 0.29;95%CI 0.12至0.69)。
- 无AKI者中,该比值最高四分位与死亡风险降低68%相关(aHR 0.32;95%CI 0.15至0.68);与CKD进展无关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The mechanisms underlying long-term sequelae after AKI remain unclear. Vessel instability, an early response to endothelial injury, may reflect a shared mechanism and early trigger for CKD and heart failure. METHODS: To investigate whether plasma angiopoietins, markers of vessel homeostasis, are associated with CKD progression and heart failure admissions after hospitalization in patients with and without AKI, we conducted a prospective cohort study to analyze the balance between angiopoietin-1 (Angpt-1), which maintains vessel stability, and angiopoietin-2 (Angpt-2), which increases vessel destabilization. Three months after discharge, we evaluated the associations between angiopoietins and development of the primary outcomes of CKD progression and heart failure and the secondary outcome of all-cause mortality 3 months after discharge or later. RESULTS: Median age for the 1503 participants was 65.8 years; 746 (50%) had AKI. Compared with the lowest quartile, the highest quartile of the Angpt-1:Angpt-2 ratio was associated with 72% lower risk of CKD progression (adjusted hazard ratio [aHR], 0.28; 95% confidence interval [CI], 0.15 to 0.51), 94% lower risk of heart failure (aHR, 0.06; 95% CI, 0.02 to 0.15), and 82% lower risk of mortality (aHR, 0.18; 95% CI, 0.09 to 0.35) for those with AKI. Among those without AKI, the highest quartile of Angpt-1:Angpt-2 ratio was associated with 71% lower risk of heart failure (aHR, 0.29; 95% CI, 0.12 to 0.69) and 68% less mortality (aHR, 0.32; 95% CI, 0.15 to 0.68). There were no associations with CKD progression. CONCLUSIONS: A higher Angpt-1:Angpt-2 ratio was strongly associated with less CKD progression, heart failure, and mortality in the setting of AKI.
引用
- Mansour SG, Bhatraju PK, Coca SG, et al. Angiopoietins as Prognostic Markers for Future Kidney Disease and Heart Failure Events after Acute Kidney Injury. J Am Soc Nephrol. 2022. PMID: 35017169. doi:10.1681/ASN.2021060757
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。